Evaluation of the effect of Enalapril on endothelial dysfunction and improvement of clinical status in migraineurs

INTERVENTION: Enalapril, 5 mg tablet, twice a day for 2 months Intervention 1: Enalapril, 5 mg tablet, twice a day for 2 months. Intervention 2: Oral placebo tablet, twice a day for 2 months. Oral placebo tablet, twice a day for 2 months Placebo Treatment ‐ Drugs CONDITION: Diseases of the nervous system/Episodic and paroxysmal disorders Migraine. ; Diseases of the nervous system/Episodic and paroxysmal disorders PRIMARY OUTCOME: Clinical status improvement. Timepoint: before intervention/1 month later/2 months later. Method of measurement: Questionnaire. Endothelial dysfunction recovery. Timepoint: before intervention/2 months later. Method of measurement: FMD with high resolution Bmode Ultrasonographic system/NOx with Greiss method/CRP with ELISA. SECONDARY OUTCOME: FMD Index. Timepoint: Before intervention,2 months later. Method of measurement: High resolution Bmode Ultrasonography. Headache durations. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire. Headache frequencies. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire. Headache severity. Timepoint: Before intervention,1 month, 2 month. Method of measurement: Questionnaire. Level of CRP. Timepoint: Before intervention,2 months later. Method of measurement: ELISA. NOx. Timepoint: before intervention,2 months later. Method of measurement: Greiss method. INCLUSION CRITERIA: INCLUSION CRITERIA: having more than three migraine attacks per month during the last 3 months, having more than 3 migraine attacks during the baseline period, debut of migraine at least one year prior to study, start of migraine before age 50 years Exclusion Criteria: Having cardiovascular (endothelial dysfunction) risk factors, undistinguishable headache interval from migraine, chronic tension‐type headache or other headache occurring on more than 15 days per month, pregnancy, breast feeding, inability to use contraceptives, presence of heart conduction block on ECG or significant ECG abnormality, presence of current or previous asthma, diabetes, decreased hepatic or renal function, hypersensitivity to active substance, significant psychiatric illness, use of daily migraine prophylactics less than 4 weeks prior to study, having tried more than or equal to three prophylactic drugs against migraine during the last 10 years, previous use of Enalapril in adequa